Initiating Coverage at Hold: A Clean Beat-and-Raise Through STELARA's First-Year Cliff, MedTech Reaccelerates to +6.1%, but the Biosimilar Curve Is Still Steepening and Talc Stays Unresolved

Rating Action: Initiating Coverage

This is our initiation report on Johnson & Johnson, the first publication in our coverage of the company. We begin coverage at Hold — with an explicitly constructive operational bias — on what is, post-Kenvue spin-off (August 2023), one of the cleanest large-cap healthcare franchises available to public-market investors: a two-segment business (Innovative Medicine + MedTech) with one of the deepest pharmaceutical pipelines in the industry, the largest installed base of cardiovascular intervention technology, and a balance sheet that funds the largest healthcare R&D budget on the planet (~15% of sales, ~$3.5B in the quarter alone).

Q2 2025 is, by any reasonable read, a strong print. JNJ delivered operational growth, raised guidance, and demonstrated through the segmental breakdown that the post-Kenvue franchise is structurally capable of growing through STELARA's loss of exclusivity — a feat management correctly noted "no other major healthcare company has done in the first year of LOE on a multi-billion-dollar product." We do not contest the operational quality; the franchise execution is on plan or ahead.

Our Hold rating is therefore a price-and-setup judgment, not a quality judgment. Five specific reservations underpin Hold rather than Outperform on initiation:

1. The STELARA biosimilar curve is still steepening. STELARA declined 43.2% in the quarter, broadly in line with management's HUMIRA-Y2-proxy framing. Critically, management explicitly told us that erosion is expected to accelerate through 2H 2025 ("similar to HUMIRAs in year 2") with additive unfavorable Part D redesign impact. The Q2 print reflects a -1,170bps STELARA drag on Innovative Medicine; the 2H drag is mechanically larger as the biosimilar penetration curve compounds. The headline IM growth rate of +3.8% understates the underlying portfolio strength — but it also understates the YoY drag still ahead of us. Q3 and Q4 IM prints will look optically softer than Q2 unless the new-launch ramps materially exceed our base case.
2. Talc remains the unpriced binary. John Reed referenced an upcoming Daubert hearing this fall, framed as a re-examination of the plaintiff-bar science underlying the litigation. We have no edge predicting the Daubert outcome, and we do not believe the equity is currently pricing meaningful tail risk on it — the equity has digested the 2024 prepackaged-bankruptcy rejection, and the market currently treats the litigation as a slow-burn financial overhang rather than a catalyst-driven binary. We view that complacency as a reasonable place to be patient rather than aggressive.
3. MedTech margin compression of ~350bps wants a Q3 datapoint. Segment-level adjusted income before tax margin in MedTech compressed from 25.7% to 22.2%, attributed to macro cost-of-products-sold factors and other-income drag. Management did not break out the precise mix of one-time vs. structural. Innovative Medicine margin compressed from 44.6% to 42.7% on STELARA mix and Intracellular acquisition costs — that we model as transient. The MedTech compression is the line we will need a Q3 read to triangulate. If it stabilizes, Hold rating compresses toward Outperform; if it continues, Hold compresses toward neutral with downside risk.
4. The post-print setup is no longer cheap. JNJ traded up ~+2.6% on the print and broke out of the multi-year $140-$167 range that had defined the equity since 2021. The breakout is consistent with the operational quality of the print, but it removes the "discounted multi-year LOE pessimism" cushion that supported the contrarian thesis entering 2025. Forward P/E at current levels embeds a successful through-cycle execution — constructive but not bargain.
5. The 2H pipeline catalysts (TAR-200, CAPLYTA-MDD, subcu RYBREVANT, icotrokindra filing, TREMFYA-UC subcu induction) are real but earnings-unvalidated. Each is a defensible 2H 2025 event with credible peak-sales math, but none has actually contributed to a print yet. Initiating Outperform on a stack of pipeline expectations — without one of them having ramped through a quarter — would compound execution risk on top of biosimilar risk. We prefer to validate at least one (TAR-200 launch trajectory; CAPLYTA-MDD approval) before pulling to Outperform.

What gets us to Outperform: (a) Q3 IM print where the new-launch portfolio (TREMFYA-IBD, RYBREVANT/LAZCLUZE, CARVYKTI, ERLEADA, SPRAVATO) more than offsets the steepening STELARA curve at the segment-level operational growth line; (b) a Daubert ruling that materially reduces talc tail risk; (c) MedTech margin stabilization at or above 22% in Q3 with a credible bridge to recovery; (d) TAR-200 launch trajectory tracking ahead of the "$1B+ peak GR sales" management framing; (e) a meaningful drawdown without thesis impairment that compresses the post-breakout multiple. What gets us to Underperform: (a) STELARA erosion acceleration meaningfully exceeds the Y2-HUMIRA proxy; (b) MedTech segment margin compresses further; (c) talc Daubert ruling adverse to JNJ with material reserve implications; (d) competitive intensity in electrophysiology (PFA from Boston Scientific, Medtronic) compresses Cardiovascular's growth rate below the +20% level we are now modeling.

Results vs. Consensus

Q2 2025 was a clean beat across the lines that matter. Revenue cleared Street consensus by ~+4.1%, adjusted EPS by ~+4.1%, and both segment lines beat — with MedTech delivering the larger positive surprise on the segmental beat-vs-bar dynamic given how soft Q1 had set the bar. Adjusted EPS declining 1.8% YoY despite the operational beat is the line that requires unpacking: the YoY decline is driven by two specific, discrete factors — (i) interest expense from the $14.5B Intracellular acquisition debt (closed April 2), and (ii) gross-profit erosion from STELARA. Neither is a thesis-relevant deterioration in underlying business quality.

Quality of Beat

• Revenue: Fully organic plus a ~160bps net acquisition contribution (Intracellular, Shockwave). Geographic mix was mixed: U.S. growth +7.8% was strong; OUS growth +0.6% reflected the OUS-heavy STELARA biosimilar penetration and COVID-19 vaccine drag. The U.S. franchise is the engine; the OUS exposure is where the biosimilar absorption is concentrated. Both segments contributed, with MedTech's QoQ acceleration the more constructive surprise.
• Adjusted EPS quality: The $2.77 beat against a $2.66 consensus is a clean operational beat, not a tax-rate-driven artifact — though the 14.7% effective tax rate (vs. 18.5% prior year) is meaningfully lower than the FY guide of 17-17.5% and bears watching. Management flagged a tax reserve adjustment driving the FY rate up; the Q2 beat would have been narrower at the FY guide rate, but still a clear beat. The headline -1.8% YoY decline is fully explained by Intracellular interest expense (debt-funded $14.5B acquisition that closed April 2, dragging a partial quarter of interest into the P&L) and STELARA gross-profit erosion. Strip these and the underlying earnings power is growing.
• Segment quality: Innovative Medicine +3.8% operational against a -1,170bps STELARA headwind implies the rest of the IM portfolio grew ~15.5% — a staggering organic growth rate for a $15B/quarter pharmaceutical business. Thirteen brands in double-digits. MedTech +6.1% with Cardiovascular at +22% is the signal that the post-Abiomed/Shockwave integrated platform is now growing competitively rather than playing catch-up.
• Cash generation: Free cash flow through 1H 2025 exceeded $6B despite elevated tax payments related to the final TCJA toll tax payment. Net debt of $32B ($51B debt - $19B cash) reflects the post-Intracellular leverage step-up. This is well within JNJ's investment-grade capacity, and management framed the leverage as funding ahead of an accelerating pipeline rather than as a structural concern.

Segment Performance

Innovative Medicine: 13 Brands in Double-Digits, STELARA Cliff Being Absorbed

Innovative Medicine sales of $15.2B (+3.8% operational) crossed the $15B/quarter threshold for the first time in JNJ's history — a milestone management correctly emphasized given that it was achieved against a -1,170bps STELARA headwind. The underlying segment growth ex-STELARA is the load-bearing analytical number: per Jennifer Taubert, "the 90% of our business that is not STELARA had extraordinarily robust growth of 15.5%." Thirteen brands grew double-digits.

"No other healthcare company has grown through the loss of exclusivity of a multibillion dollar product in the first year. In our case, STELARA, and yet that is exactly what we are doing. And for the second quarter in a row." — Joaquin Duato, Chairman and CEO

Oncology — the engine driving the long-term thesis: Operational growth of +22.3% in oncology, with the multiple myeloma franchise (DARZALEX +21.5% on continued share gains of ~4.1pts; CARVYKTI $439M, +100%+ with sequential growth of +17.9% as OUS expansion continues; TECVAYLI +22.4%, TALVEY +54.3%) the core anchor. Approximately 80% of myeloma patients today receive a JNJ medicine at some point in their treatment journey. RYBREVANT/LAZCLUZE ($179M, +100%+) is in the early innings of EGFR-mutant frontline NSCLC and is now the #1 intent-to-prescribe regimen per management's market research, with penetration in nearly 100% of high-priority accounts and ~25% of patients across lines of therapy initiating on the regimen. ERLEADA grew +21% in prostate. The 2030 ambition: $50B oncology business, +#1 in the category. Q2 puts that on glide path.

TAR-200 — the disconnect with consensus: Taubert explicitly called out TAR-200 (drug-releasing intravesical system for non-muscle invasive bladder cancer) as "probably the asset that has the biggest disconnect between our internal forecasts and what the Street expects" — with management modeling 2028 numbers "at least 3x higher" than Street consensus. FDA priority review is in hand; first launch is expected later this year (Q4 2025). Management peak GR sales framing: "$1B+." The asset benefits from JNJ's combined Innovative Medicine + MedTech expertise (a chemotherapy delivery device leveraging device engineering capabilities) — one of the few practical post-Kenvue synergies between the two segments.

Immunology — TREMFYA absorbing STELARA's strategic role: TREMFYA grew 30.1% on continued IBD launch uptake (Crohn's and ulcerative colitis), with peak-sales framing of "$10B+ annually" — a number that, if achieved, mathematically replaces a meaningful share of the STELARA revenue base on a multi-year horizon. Reed correctly noted that STELARA had ~70% of its prescriptions in IBD — meaning TREMFYA's IBD penetration is, in a meaningful sense, the strategic absorption of STELARA's franchise. Subcutaneous induction approval for ulcerative colitis is expected later in 2025; psoriatic arthritis filing in Q3.

STELARA itself declined 43.2% in line with the HUMIRA-Y2 erosion proxy plus Part D redesign impact. Management explicitly modeled the curve to steepen through the back half of the year. This is the single biggest 2H 2025 modeling input: the IM segment's headline operational growth rate will likely re-compress in Q3 and Q4 even if the new-launch ramps continue at current pace, because the YoY STELARA base erodes at an accelerating rate.

Neuroscience — CAPLYTA acquisition contributing, SPRAVATO accelerating: Intracellular's CAPLYTA closed April 2 and is now contributing across schizophrenia and bipolar depression indications, with the anticipated MDD adjunctive approval expected later this year as the next franchise inflection. Management's peak-sales framing: $5B+. SPRAVATO grew 53% on continued strong demand in difficult-to-treat depression — an underdiscussed asset in our framework, with significant headroom in the treatment-resistant depression population.

Long-acting injectables (the legacy psychiatry portfolio) declined 6.3% on Part D redesign and unfavorable patient mix — an idiosyncratic drag that should normalize but is worth flagging.

IM segment margin: 42.7% vs. 44.6% prior year. The compression is driven by negative mix (lower-margin Intracellular acquisition early-life dilution) and STELARA-related cost-of-products-sold dynamics. We model this as transient and expect normalization through 2026 as the Intracellular integration completes and the STELARA mix-shift stabilizes.

MedTech: +6.1% Operational, the Cardiovascular Engine, the Margin Watch

MedTech sales of $8.5B (+6.1% operational; +8.0% U.S., +4.1% OUS) was a meaningful step-up from Q1 and the line of the print where management most clearly delivered against the "we have work to do" framing they had carried into 2025. Acquisitions (primarily Shockwave, which lapped to end-May) contributed ~200bps to growth. The segmental breakdown:

Cardiovascular — the franchise winning: +22% operational growth in the quarter. The decomposition: Abiomed +16.9% with continued Impella adoption (the cardiogenic shock indication continues to scale, with the recent ACC/AHA guideline support for Impella use a structural tailwind); Shockwave double-digit growth with Javelin and E8 catheter introductions, on track for the "$13B platform by year-end" framing; electrophysiology +9.8% on Varipulse (PFA) adoption — now over 10,000 cases globally with neurovascular event rate <0.5%, consistent with published rates across competitive PFA platforms. The dual-energy Thermocool SmartTouch SF catheter (PFA + RF) had its first European cases in Q2 and is the next-generation catheter that closes the technology gap with Boston Scientific's Farapulse and Medtronic's PulseSelect.

"EP is currently, I think it's fair to say probably the most exciting category in MedTech. And let me be clear, we are not rolling over. We are, in fact, increasingly confident that our 30 years of experience, our full portfolio of offerings positions us well to continue to retain our global leadership position over the long term." — Tim Schmid, EVP Worldwide Chairman MedTech

The EP commentary deserves particular attention because the competitive narrative coming into 2025 was that JNJ was structurally losing the PFA race. Q2 reframes that: the $5B EP base grew +9.8%, sequentially +9% over Q1, with Varipulse sustaining adoption and the dual-energy STSF catheter providing a credible next-product path. Schmid's emphatic "we are not rolling over" tone was the clearest example of management push-back on a Street narrative we observed on the call.

Surgical Vision & Vision — the turnaround: Vision +4.6% overall, with Surgical Vision +8.9% (Tecnis Odyssey IOL driving second consecutive quarter of double-digit growth in U.S., +13% in U.S.). Contact lenses +2.9% on the ACUVUE OASYS family with the multifocal-for-astigmatism launch the late-2025 catalyst (the world's first daily disposable lens for both astigmatism and presbyopia). This is a genuine turnaround story that has gone underappreciated through the Vision Care de-leveraging cycle.

Surgery — modest growth, robotic platform on the horizon: +1.8% with technology penetration in wound closure and biosurgery (multibillion-dollar businesses growing close to 7%) offsetting competitive pressure in energy and China VBP impact. The Ethicon 4000 surgical stapler launched in Q2 and is the precursor to its exclusive use on the OTTAVA robotic surgery system. OTTAVA completed first clinical cases (cardiac bypass surgeries in Houston) and is on track for FDA de novo submission in Q1 2026 — the timeline management explicitly clarified has not slipped despite Street speculation.

Orthopedics — the soft spot: -1.6% operational, dragged by competitive pressure, the in-flight transformation program, and China VBP. New product launches (Atune Revision Hinge, Vault plating system) are expected to contribute to the back half of 2025, but Orthopedics remains the segment we view as structurally challenged within MedTech's portfolio composition.

MedTech segment margin: 22.2% vs. 25.7%, a ~350bps compression attributed to macro cost-of-products-sold pressure and other-income drag. This is the line we will need a Q3 datapoint to triangulate. Tariff exposure was reset to $200M (down from $400M, MedTech-only) on the call, with the differential being reinvested into pipeline acceleration. The implication: the FY2025 MedTech margin compression is likely real but should not extend through 2026 once the tariff and cost-of-products-sold pressures stabilize.

Key Topics & Management Commentary

Overall Management Tone: Confident and notably less defensive than the Q1 print would have led one to expect. Joaquin Duato led with the "strong second quarter" framing and immediately pivoted to the diversification thesis — the only major healthcare company operating in both MedTech and Innovative Medicine sectors. The tone choice is consistent with a management team that is increasingly comfortable defending the post-Kenvue narrative and is now playing offense on capital deployment (Intracellular, the $55B U.S. investment commitment, the OBBBA tax provisions enabling permanent R&D expensing). The pipeline confidence from John Reed — "I'd be willing to bet likely beat the upper end of the growth targets we conveyed at our 2023 enterprise business review" — was the most assertive forward-looking statement we heard on the call.

The 13 Double-Digit Brands and the Portfolio Depth Argument

The single most important analytical takeaway from the prepared remarks is the breadth of the in-line portfolio's growth. Thirteen brands in double-digits. The list spans oncology (DARZALEX, CARVYKTI, TECVAYLI, TALVEY, ERLEADA, RYBREVANT/LAZCLUZE), immunology (TREMFYA), neuroscience (SPRAVATO, CAPLYTA), and cardiovascular (Abiomed, Shockwave, Varipulse-EP, Tecnis Odyssey IOL). This is what the post-Kenvue franchise is supposed to look like — a portfolio sufficiently diversified that no single asset's ramp or headwind is the franchise's whole story.

The strategic point that bears emphasizing: the breadth is engineered, not accidental. JNJ's R&D budget (~$3.5B in the quarter, ~15% of sales, among the highest in healthcare) has been deliberately allocated to multiple late-stage programs over the past decade. The current cohort of growth drivers reflects 2015-2020 R&D investment decisions; the next cohort (TAR-200, icotrokindra, CAPLYTA-MDD, dual-specific antibodies, the trispecific in myeloma) reflects 2018-2023 decisions. The pipeline is the through-line.

The STELARA Curve and the Y2-HUMIRA Proxy

Management's framing of the STELARA biosimilar erosion as following the "year 2 of HUMIRA" proxy is the analytical anchor for our 2H 2025 model. STELARA declined 43.2% in Q2; HUMIRA's Y2 erosion accelerated meaningfully through quarters 3 and 4 of biosimilar competition. Plus the additive Part D redesign drag (which compresses revenue capture even on stable script counts). Management's expectation is that STELARA's 2H decline will be steeper than the 1H decline.

"We maintain the assumption that STELARA's large biosimilar competition will accelerate throughout the year with erosion similar to HUMIRAs in year 2, which is still our proxy with the additive unfavorable impact of Part D redesign." — John Reed (substituting for CFO Joe Wolk in the prepared remarks)

Embedded in this framing is the bull-case offset: management explicitly guided MedTech and IM to both grow faster in 2H than 1H. For IM, the offsetting drivers must be the new-launch portfolio (TREMFYA-IBD, RYBREVANT/LAZCLUZE, CARVYKTI capacity expansion, ERLEADA, CAPLYTA-MDD on approval) ramping fast enough to overcome the steepening STELARA curve. The math is achievable but requires every new launch to be at or above plan.

The OTTAVA Submission Timeline Clarification

Tim Schmid pushed back firmly on a Street narrative that had been circulating — that the OTTAVA robotic surgery system FDA de novo submission timeline had slipped. His clarification: "we haven't pushed out our timelines at all. In fact, we've met all of the milestones we've communicated to the market." Submission late last year, approval late last year, clinical trials starting Q1 2025, de novo submission in Q1 2026.

This matters because the Street had begun pricing in OTTAVA delay risk on top of MedTech's broader execution concerns. The clarification removes one analyst-driven overhang. OTTAVA enters a robotic-surgery market where Intuitive Surgical's da Vinci installed base is the entrenched competitor; JNJ's strategy is to differentiate on twin-motion architecture, Ethicon-instrumentation exclusivity, and integration with the Polyphonic open digital ecosystem. Whether this differentiation is sufficient to capture meaningful share against da Vinci is the medium-term unknown; but the near-term concern (timeline slip) is now off the table.

Tariff Reset: $400M → $200M, Reinvested Not Dropped

Tariff exposure was reset from $400M (the Q1 framing) to $200M (now MedTech-only, no Innovative Medicine exposure currently included — though MFN policy remains an excluded risk). The differential is being reinvested into pipeline acceleration and new-product launches rather than dropped to the bottom line.

This is a deliberate signal about capital allocation philosophy. Management could have flowed the tariff windfall through to EPS guidance and beat-and-raised by a larger amount; they chose instead to reinvest. The signaling is: pipeline acceleration is the highest ROIC use of marginal cash flow, and the management team is willing to absorb the optical EPS cost to fund it. We view this favorably from a long-term thesis standpoint — reinvesting at JNJ's R&D ROIC is preferable to optical EPS optimization — though it does mean the Q2 beat-and-raise was not as large as it could have been.

The $55B U.S. Investment Commitment and the OBBBA Tax Provisions

Management spent meaningful time on the One Big Beautiful Bill Act (OBBBA) tax provisions: permanent expensing for domestic R&D, permanent bonus depreciation, 100% expensing of qualified production property. These provisions enable JNJ's $55B U.S. investment commitment over four years — including a newly planned facility in North Carolina. The commitment is structurally supportive of the company's "manufacture in the U.S. all medicines consumed in the U.S." goal that responds to potential pharma tariff regimes.

The 1% increase to the global effective tax rate in 2026 (from GILTI rate moving from 10.5% to 12.6%) is the offsetting drag. Net of these moving parts, we model FY2026 effective tax rate at ~18-18.5%, modestly higher than FY2025's guided 17-17.5%.

Guidance & Outlook

The headline guide raise is meaningful but the composition is what bears unpacking. Of the $0.25 EPS raise, $0.08 is operational (the underlying business outperforming) and $0.17 is the FX tailwind from a weaker dollar (euro spot reset from 1.11 to 1.17 since the prior call). The operational beat is real but not as large as the headline EPS raise suggests — investors who treat the full $0.25 as operational are over-extrapolating.

The $900M sales guide raise (operational) is $200M larger than the trailing-12-month sales beat would mechanically imply — meaning management is calling for an acceleration in the back-half through both new product introductions and the in-line portfolio. This is the line we view as the most credible piece of the guide. The +1pt operational growth raise (3.5-ish to 4.5-5.0%) is not aggressive given the Q2 performance.

The +300bps operating margin improvement reaffirmation despite YTD compression is the line that requires the most management explanation. Per Reed: the H2 improvement is driven by efficiency programs, the lap of nonrecurring 2H 2024 IP R&D charges, and known tariff exposure of $200M. We accept the framing but flag that this requires meaningful H2 margin expansion — a stretchy goal given MedTech's Q2 segment-margin compression.

What we don't have: Specific Q3 revenue or EPS guidance. JNJ provides full-year guidance only. Our base case for Q3 2025: revenue ~$23.5-24B (operational growth in the 5-6% range as the new-launch portfolio accelerates and the STELARA YoY base steepens), adjusted EPS in the $2.65-2.80 range (depending on the pace of MedTech margin recovery and the size of the back-half operating leverage). Q4 will be the Hopper-of-the-pharma-cycle quarter where new launches need to substantially fund the IM segment growth as STELARA's YoY base bottoms.

Analyst Q&A Highlights

Drivers of the Guide Raise

• Christopher Schott, JPMorgan: Asked Wolk for the decomposition of guidance upside between the IM and MedTech segments and which franchises specifically are driving. The company turned the answer over to Jennifer Taubert and Tim Schmid, both of whom emphasized broad portfolio strength rather than concentrated drivers. Taubert: 13 brands in double-digit growth, with DARZALEX, CARVYKTI, ERLEADA, RYBREVANT/LAZCLUZE, TREMFYA-IBD, SPRAVATO, and CAPLYTA the standouts. Schmid: Cardiovascular at +22% the primary MedTech contributor, with Vision and Surgery contributing positively.
  Assessment: The non-pointed answer is the right answer here. The strategic point is that the guide raise is broadly sourced rather than dependent on any single asset's overperformance — which is a different (and analytically stronger) signal than the one the question implicitly invited.

Oncology — The $50B by 2030 Ambition and TAR-200

• Terence Flynn, Morgan Stanley: Asked Taubert about the deltas vs. consensus in the $50B-by-2030 oncology framing, and on the subcu RYBREVANT CRL response timeline. Taubert highlighted TAR-200 as the largest specific consensus disconnect — with management's 2028 internal forecasts "at least 3x higher" than Street consensus — and confirmed the subcu RYBREVANT CRL was a manufacturing-related question (not clinical), now responded to, with approval expected in 2H.
  Assessment: The TAR-200 disclosure is the most actionable analytical takeaway from the call. If management's internal numbers are 3x Street consensus on a 2028 basis, the asset is mathematically a meaningful upside lever to the long-term IM thesis — and it begins launching in 2H 2025. We will watch the launch trajectory closely as our highest-leverage signal in the back-half.
• Alexandria Hammond, Wolfe Research: Asked specifically about TAR-200 launch strategy — sales force training, supply chain, patient access, urologist education. Taubert highlighted the cross-segment innovation (engineering capability from MedTech contributing to a pharmaceutical product launch), the addressable population (600,000 new diagnoses + 400,000 recurrent annually), and the J&J Institute's training program for urologists. Initial indication: post-BCG-failure, with broader non-muscle-invasive expansion to follow.
  Assessment: The launch readiness narrative is credible. The structural advantage of JNJ's combined IM + MedTech expertise is a genuine differentiator on this specific asset that few peers can replicate.

FY2026 Setup and Margin Trajectory

• Larry Biegelsen, Wells Fargo: Asked Wolk about whether 2026 operational growth could exceed 2025's 3.5%-ish adjusted operational rate, and whether operating margin can expand beyond the implied 32.8% in 2025 guidance. Wolk declined to provide 2026 guidance but framed 2026 as "better than 2025" based on momentum from in-line brands receiving new indications and the planned new product introductions. On margins, he invoked the principle of growing the bottom line consistent with or better than the top line, but reserved formal commentary until later in the year.
  Assessment: The "2026 better than 2025" framing is constructive but the absence of margin commitment is the line that bears watching. Part D redesign drag and the ongoing tariff uncertainty make the margin question genuinely difficult to commit to in mid-2025.

Pharma Tariffs and U.S. Manufacturing Capacity

• Asad Haider, Goldman Sachs: Asked about pharma tariff implications, the announced administration framework starting at low rates with a one-year build window, and JNJ's U.S. manufacturing flexibility. Joaquin Duato responded by reframing the question around the OBBBA tax provisions and JNJ's $55B U.S. investment commitment, with a goal of manufacturing in the U.S. all medicines consumed in the U.S. by the completion of the four-year plan.
  Assessment: Duato deliberately did not engage with the specifics of tariff scenarios, choosing instead to position JNJ as proactively building U.S. manufacturing capacity. The implicit message: JNJ believes it will be largely insulated from pharma tariff impact by the time tariffs are meaningful. This may be optimistic; the four-year buildout timeline does not match the more aggressive tariff implementation timelines the administration has signaled.

OTTAVA, Varipulse, and the EP Competitive Picture

• Shagun Singh Chadha, RBC Capital Markets: Asked about the perceived OTTAVA submission timeline pushout and physician feedback on Varipulse adoption. Schmid corrected the OTTAVA timeline narrative emphatically (no pushout; on track) and used the EP question to deliver the most extended defense of JNJ's electrophysiology position we have heard from management to date — emphasizing the 10,000+ Varipulse cases globally with neurovascular event rate <0.5%, the dual-energy STSF catheter as next-product, the Cardo mapping system installed base of 5,000 systems as a structural moat, and the OmniPulse focal catheter as future-product.
  Assessment: The EP defense was the longest and most assertive answer of the call, and reflects a management team that knows the Street narrative on PFA share loss is the largest analyst-driven concern hanging over the stock. The pushback was credible: +9.8% Q2 growth on a $5B EP base is not what an incumbent losing share would print. Schmid's "we are not rolling over" is a tone signal we weight meaningfully.

MedTech Trajectory to High-Single-Digit Growth

• Danielle Antalffy, UBS: Asked Schmid about the trajectory toward potentially high-single-digit MedTech growth through 2026-2027 as the new product launches contribute. Schmid framed Cardiovascular and Surgery (especially with OTTAVA in robotic) as the two largest growth drivers, Vision as mid-to-high-single-digit, and Orthopedics as the one segment requiring continued performance improvement. He reiterated the EBR target of +5% to +7% upper-range operational growth through 2027 but declined to extend further.
  Assessment: The +5-7% upper-range framing through 2027 is the most concrete forward MedTech growth guidance management has provided. If MedTech can deliver in the +6-7% range with stable margins, the segment becomes a meaningfully larger contributor to enterprise value than current Street modeling reflects.

IBD Combination Therapy and the Immunology Pipeline

• Vamil Divan, Guggenheim Securities: Asked Reed about the JNJ-4804 (IL-23 + TNF dual-antibody) IBD readouts and the icotrokindra (oral IL-23R inhibitor) data timing. Reed confirmed the JNJ-4804 Phase IIb readouts (Crohn's and ulcerative colitis) are expected mid-2025, with potential to break through traditional efficacy ceilings in difficult-to-treat IBD. icotrokindra Phase III campaigns in both UC and Crohn's are gearing up based on Phase II proof-of-concept data, with ulcerative colitis data to be presented at a medical meeting later this year.
  Assessment: The combination-antibody approach in IBD is a genuine differentiation strategy and represents the next layer of immunology growth beyond TREMFYA. icotrokindra as an oral peptide with biologic-equivalent efficacy would be a category-defining asset if the Phase III data confirm Phase II. These are 2026-2027 thesis levers, not 2025 print levers.

What They're NOT Saying

1. Specific 2H STELARA decline expectations. Management framed the 2H trajectory as "similar to HUMIRAs in year 2" but did not provide a specific Q3 or Q4 STELARA revenue expectation. The HUMIRA Y2 erosion curve accelerated meaningfully through quarters 3 and 4 of biosimilar competition (a -55% to -65% range by exit-year). If STELARA tracks that pattern, Q4 2025 STELARA revenue could be down ~55-60% YoY — meaningfully steeper than Q2's -43.2%. Management is choosing not to specify; we read the silence as conservative.
2. The talc Daubert hearing's expected outcome and the implications of an adverse ruling. Reed referenced the Daubert hearing "this fall" and framed it positively as a re-examination of "junk science." But there is no contingency framing — no discussion of incremental reserve build, no settlement-floor articulation, no path to resolution beyond the Daubert outcome. The talc litigation has been a slow-burn financial overhang since the 2024 prepackaged-bankruptcy rejection; we read the management posture as confidence in the Daubert outcome, but the asymmetric tail risk to an adverse ruling remains unacknowledged.
3. MFN drug pricing policy impact. Reed explicitly noted that current guidance "does not include the impact of the most favored nation concepts" while also noting JNJ's directional alignment with the policy goal. This is the largest unmodeled regulatory risk in our framework. If MFN drug pricing materializes in any binding form (international reference pricing, mandatory most-favored-nation rebates, or related mechanisms), it would compress Innovative Medicine's revenue base meaningfully. The exclusion from guidance is appropriate given policy uncertainty, but it is a real tail risk.
4. The next biosimilar wave. STELARA is the current LOE event. The next major LOE in JNJ's portfolio is OPSUMIT (pulmonary hypertension, 2026 patent expiry in U.S.) followed by IMBRUVICA (the IBD/oncology asset, 2027-2028 LOE depending on geography). Management did not discuss the 2026-2028 LOE pipeline. We expect this to become a more prominent management topic in subsequent calls.
5. Specific MedTech segment margin recovery trajectory. Schmid did not provide a specific Q3 or Q4 MedTech segment margin expectation, despite the ~350bps Q2 compression being one of the most analytically important datapoints in the print. The framing of "macro cost-of-products-sold pressure" is general; we would prefer a more specific decomposition. We treat this as a watchpoint for the Q3 print.

Market Reaction

• Trading day response (July 16, 2025): JNJ traded up approximately +2.6% on the day of the print, a constructive but not euphoric response that reflects the clean beat-and-raise mechanism. The move broke the multi-year $140-$167 trading range that had defined JNJ since 2021, with the stock printing above $167 on positive close.
• Range-breakout context: The technical breakout above the $140-$167 range is meaningful because it removes the "stuck since 2021" overhang that had been a persistent buy-side concern through the post-Kenvue period. The breakout is consistent with the operational quality of the print and the through-cycle visibility that the guide raise provides.
• Pre-print expectations: The Street had been positioned cautiously into the print on STELARA cliff concerns and MedTech execution skepticism following the soft Q1 read. The clean operational beat and the Q1 → Q2 MedTech sequential acceleration (+4.4pts) were the two specific datapoints that surprised positively against that cautious setup.
• Subsequent price action context (informational): JNJ continued to grind higher through late-July and into early August on continued constructive sell-side reaction, with the stock printing all-time highs above $170. The breakout has held.

The market reaction is rational and consistent with the operational quality of the print. The +2.6% move is large enough to acknowledge the beat-and-raise but small enough that the equity is not over-extrapolated relative to the 2H STELARA risk and the unresolved talc overhang. From an entry-point perspective, the post-print setup is no longer compressed — the stock has moved from "trading at the bottom of a multi-year range" to "breaking out at the top." This shifts the risk/reward marginally less constructive at current levels and is one of the inputs to our Hold rating.

Street Perspective

Debate: Will the H2 STELARA cliff overwhelm the new-launch portfolio?

Bull view: The 13 double-digit-growth brands, the +15.5% growth in the IM portfolio ex-STELARA, and the explicit management framing of accelerating new-launch contribution in 2H all point to the new portfolio successfully overwhelming the STELARA decline. TREMFYA-IBD ramp, RYBREVANT/LAZCLUZE penetration, CARVYKTI capacity expansion, and CAPLYTA-MDD approval all stack into the back-half operational growth story. The IM segment can grow 4-5% operationally in 2H even with a steepening STELARA curve.

Bear view: The HUMIRA Y2 proxy implies STELARA YoY declines steepening to -55% to -65% through 2H. The new launches, however well-positioned, are not large enough in absolute revenue terms to offset that magnitude of base erosion in the near term. The IM segment growth rate decelerates from +3.8% in Q2 to potentially low-single-digit or flat in Q4, exposing the franchise to "growth gap" optics that compress the multiple regardless of underlying portfolio quality.

Our take: Bull view is closer to right on a full-year basis but bear view captures the legitimate optics risk in the Q4 print specifically. We model IM segment operational growth of approximately +3-4% in Q3 and +1-3% in Q4, with full-year IM landing in the +3-4% operational range. The optics risk is real and is one of the inputs to our Hold rating — we would rather own the franchise after the Q4 STELARA-trough print is in hand than ahead of it.

Debate: Has JNJ won the EP battle or merely stabilized?

Bull view: +9.8% EP growth on a $5B base is what an incumbent winning the next-generation transition prints. Varipulse adoption is ramping, the dual-energy STSF catheter closes the technology gap, the Cardo mapping installed base is a structural moat, and management is investing aggressively. JNJ retains global EP leadership through the PFA transition.

Bear view: The PFA market is still in early adoption; Boston Scientific's Farapulse and Medtronic's PulseSelect are taking share in U.S. centers where they have first-mover advantage. JNJ's +9.8% growth reflects continued market expansion (the PFA category is growing >30% YoY in many geographies) more than incumbent share retention. Once category growth normalizes, JNJ's relative share trajectory will be more visible — and the early datapoints suggest share loss.

Our take: The truth is in the middle. JNJ has stabilized its EP position through Varipulse, but it has not retaken the lost ground in U.S. centers where Farapulse arrived first. The dual-energy STSF catheter is the next-product test — if it accelerates U.S. share recapture in 2026, the bull view validates; if it merely holds existing share, the franchise becomes a "competitive growth" rather than "incumbent defense" story. We model EP growth in the +8-12% range through 2026 with a wide confidence interval.

Debate: Is the multiple discounted enough at current levels?

Bull view: JNJ trades at a meaningful discount to large-cap pharma peers on forward earnings, despite a more diversified franchise composition (IM + MedTech), a deeper pipeline, and a lower revenue concentration than single-asset pharmaceutical names. The breakout from the $140-$167 range reflects the early stages of multiple expansion as the post-Kenvue de-rating reverses. Further multiple expansion is the principal source of upside.

Bear view: The multiple discount reflects real structural concerns — the unresolved talc litigation, MFN policy uncertainty, the 2026-2028 secondary LOE wave, and the MedTech execution variance. The breakout reflects relief on Q2 quality, not structural revaluation. Once the next legitimate concern surfaces (Q3 STELARA acceleration, talc Daubert ruling, MFN policy clarity), the multiple compresses back into the prior range.

Our take: The breakout is real but the bear's structural concerns are also real. We treat the equity as fairly priced at current levels for an investor with a 12-18 month horizon, with neither obvious upside nor obvious downside on a base-case forward EPS algorithm. This is the textbook setup for a Hold rating — high-quality franchise, full-but-not-stretched multiple, real but bounded tail risks.

Model Implications

Valuation framing: JNJ's post-print breakout to above $167 places the equity at a forward P/E in the high-15x range on FY2026 estimates — modestly below large-cap pharma peers and meaningfully below the broader market multiple. The discount is justified by the real but bounded structural concerns (talc, MFN, secondary LOEs) rather than by execution quality. We do not see the equity as obviously cheap at current levels; we see it as fairly priced for a high-quality, well-diversified franchise with credible through-cycle visibility. This is the textbook setup for a Hold rating — a franchise we want to own at the right price, with the right price being either at lower levels (a 10-15% drawdown without thesis impairment) or after one of the binary risks resolves favorably (talc Daubert).

The asymmetric scenarios that would change our rating: (i) Q3 print delivering accelerating IM operational growth despite a steepening STELARA curve, with MedTech margin stabilizing at or above 22% → Outperform pull; (ii) talc Daubert ruling materially reducing tail risk → Outperform pull; (iii) TAR-200 launch trajectory in Q4 tracking ahead of the "$1B+ peak" framing → Outperform pull; (iv) MedTech segment margin compresses further in Q3 → Hold-with-downside-bias risk; (v) STELARA erosion meaningfully exceeds the Y2-HUMIRA proxy → Hold-with-downside-bias risk.

Thesis Scorecard at Initiation

Overall: Six bull points are confirmed or tentatively confirmed by this print, and six bear points are live, neutral, or in watch mode. The central tension is that operational execution is strong and the through-cycle visibility is credible, but the equity has now broken out of its multi-year compressed range and the binary tail risks (talc, MFN) remain unresolved. The Hold rating reflects price-and-setup judgment on a high-quality franchise, with explicitly constructive operational bias.

Action: Initiating at Hold (constructive bias). Upgrade triggers: (a) Q3 print delivering accelerating IM operational growth with MedTech margin stabilizing at or above 22%; (b) talc Daubert ruling that materially reduces tail risk; (c) TAR-200 launch trajectory in Q4 tracking ahead of management framing; (d) drawdown of 10-15% without thesis impairment that compresses the post-breakout multiple. Downgrade triggers: (a) STELARA erosion meaningfully exceeds the Y2-HUMIRA proxy; (b) MedTech segment margin compresses further in Q3; (c) talc Daubert ruling adverse with material reserve implications; (d) electrophysiology growth rate deceleration suggesting Varipulse share losses. We will revisit on the Q3 2025 print.